The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer

Not Applicable

• Conditions: Primary Liver Cancer
• Interventions: Dietary Supplement: non-BCAA protein supplement; Dietary Supplement: Branched-chain amoni acids (BCAA)

• Registration Number: NCT02327819
• Lead Sponsor: Tel-Aviv Sourasky Medical Center

Brief Summary

Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect of BCAA on existing liver cancer is unknown.

The participants (post curative intent surgery) will be supplemented with either BCAA/non-BCAA-enriched protein supplement. The intervantion will go on for 2 years or until a new liver tumor is found.

Detailed Description

Not available

Study Timeline

• Status Verified: 2014-12
• Study First Submitted: 2014-12-24
• Study First Submitted QC: 2014-12-24
• Last Update Submitted: 2014-12-24
• Study First Posted: 2014-12-30
• Last Update Posted: 2014-12-30
• Study Start: 2015-01
• Primary Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• diagnosed primary liver cancer
• viral or Nonalcoholic Steatohepatitis Cirrhosis
• Cirrhosis rated Child-Pugh A
• liver cancer rated Barcelona Clinic Liver Cancer (BCLC) A

Exclusion Criteria

• Age (over 65)
• liver condition rated Child-Pugh B/C
• GI/Absorption issues
• patients given a treatment before surgery

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
non-BCAA protein supplement	non-BCAA protein supplement	non-BCAA protein supplement
BCAA supplement	Branched-chain amoni acids (BCAA)	Branched-chain amino acids supplement, 12 g/day

Primary Outcome Measures

Name	Time	Method
time until a new liver tumor is found	2 years

Trial Locations

Locations (1)

Clinical Nutrition Unit, Sourasky Medical Center; 🇮🇱 Tel Aviv, Israel